XML 13 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 7,317 $ 11,814
General and administrative 4,119 3,959
Total operating expenses 11,436 15,773
Loss from operations (11,436) (15,773)
Total other income (expense), net 644 892
Consolidated net loss (10,792) (14,881)
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited 1 1
Net loss attributable to aTyr Pharma, Inc. $ (10,791) $ (14,880)
Net loss per share - basic $ (0.11) $ (0.17)
Net loss per share - diluted $ (0.11) $ (0.17)
Shares used in computing net loss per share, basic 98,043,839 86,485,126
Shares used in computing net loss per share, diluted 98,043,839 86,485,126